These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 37149462)

  • 1. Reply to Alireza Ghoreifi and Hooman Djaladat's Letter to the Editor re: Daniel D. Shapiro, Jose A. Karam, Logan Zemp, et al. Cytoreductive Nephrectomy Following Immune Checkpoint Inhibitor Therapy Is Safe and Facilitates Treatment-free Intervals. Eur Urol Open Sci 2023;50:43-6.
    Shapiro DD; Karam JA; Master VA; Zemp LW; Sexton WJ; Matin SF; Spiess PE; Jason Abel E
    Eur Urol; 2023 Aug; 84(2):e55-e56. PubMed ID: 37149462
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Daniel D. Shapiro, Jose A. Karam, Logan Zemp, et al. Cytoreductive Nephrectomy Following Immune Checkpoint Inhibitor Therapy Is Safe and Facilitates Treatment-free Intervals. Eur Urol Open Sci 2023;50:43-6.
    Ghoreifi A; Djaladat H
    Eur Urol; 2023 Aug; 84(2):e53-e54. PubMed ID: 37149463
    [No Abstract]   [Full Text] [Related]  

  • 3. Reply to Daniel D. Shapiro, Jose A. Karam, Viraj A. Master, et al.'s Letter to the Editor re: Wesley Yip, Alireza Ghoreifi, Thomas Gerald, et al. Perioperative Complications and Oncologic Outcomes of Nephrectomy Following Immune Checkpoint Inhibitor Therapy: A Multicenter Collaborative Study. Eur Urol Oncol. Eur Urol. Onc. 2023;604-610.
    Yip W; Ghoreifi A; Djaladat H
    Eur Urol Oncol; 2023 Dec; 6(6):637. PubMed ID: 37316397
    [No Abstract]   [Full Text] [Related]  

  • 4. Reply to Alireza Ghoreifi and Hooman Djaladat's Letter to the Editor re: Fredrik Liedberg, Petter Kollberg, Marie Allerbo, et al. Preventing Parastomal Hernia After Ileal Conduit by the Use of a Prophylactic Mesh: A Randomised Study. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.07.033.
    Liedberg F; Kollberg P; Allerbo M; Baseckas G; Brändstedt J; Gudjonsson S; Hagberg O; Håkansson U; Jerlström T; Löfgren A; Patschan O; Sörenby A; Bläckberg M
    Eur Urol; 2020 Nov; 78(5):e186-e187. PubMed ID: 32950295
    [No Abstract]   [Full Text] [Related]  

  • 5. Re: Wesley Yip, Alireza Ghoreifi, Thomas Gerald, et al. Perioperative Complications and Oncologic Outcomes of Nephrectomy Following Immune Checkpoint Inhibitor Therapy: A Multicenter Collaborative Study. Eur Urol Oncol. Eur Urol. Onc. 2023;604-610.
    Shapiro DD; Karam JA; Master VA; Sexton WJ; Matin SF; Spiess PE; Abel EJ
    Eur Urol Oncol; 2023 Dec; 6(6):638-639. PubMed ID: 37268448
    [No Abstract]   [Full Text] [Related]  

  • 6. Re: Ziad Bakouny, Talal El Zarif, Shaan Dudani, et al. Upfront Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors or Targeted Therapy: An Observational Study from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol 2023;83:145-51.
    Li J; Chen B; Cao D
    Eur Urol; 2023 Sep; 84(3):e75. PubMed ID: 37270390
    [No Abstract]   [Full Text] [Related]  

  • 7. Reply to Alireza Ghoreifi and Hooman Djaladat's Letter to the Editor re: Isamu Tachibana, Sean Q. Kern, Antoin Douglawi, et al. Primary Retroperitoneal Lymph Node Dissection for Patients with Pathologic Stage II Nonseminomatous Germ Cell Tumor-N1, N2, and N3 Disease: Is Adjuvant Chemotherapy Necessary? J Clin Oncol. In press. https://doi.org/10.1200/JCO.22.00118: Is Retroperitoneal Lymph Node Dissection Without Adjuvant Chemotherapy Enough for All Patients with Pathologic Stage II Nonseminoma Germ Cell Tumor?
    Tachibana I; Kern SQ; Douglawi A; Tong Y; Mahmoud M; Masterson TA; Adra N; Foster RS; Einhorn LH; Cary C
    Eur Urol; 2023 Jan; 83(1):e20-e21. PubMed ID: 36195478
    [No Abstract]   [Full Text] [Related]  

  • 8. Reply to Eduard Roussel, Riccardo Bertolo, Chiara Ciccarese, et al's Letter to the Editor re: E. Jason Abel, Viraj A. Master, Philippe E. Spiess, et al. The Selection for Cytoreductive Nephrectomy (SCREEN) Score: Improving Surgical Risk Stratification by Integrating Common Radiographic Features. Eur Urol Oncol. 2023;6:266-274.
    Abel EJ; Master VA; Spiess PE; Raman JD; Shapiro DD; Sexton WJ; Zemp L; Patil D; Lauer K; Allen GO; Matin SF; Karam JA
    Eur Urol Oncol; 2024 Apr; 7(2):302-303. PubMed ID: 38000932
    [No Abstract]   [Full Text] [Related]  

  • 9. Reply to Nirmish Singla and Vitaly Margulis's Letter to the Editor re: Geraldine Pignot, Antoine Thiery-Vuillemin, Jochen Walz, et al. Nephrectomy After Complete Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma: A New Surgical Challenge? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.12.018. The Next Surgical Frontier in Kidney Cancer: Nephrectomy After Immune Checkpoint Inhibition: Nephrectomy After Immunotherapy: The Duration of Treatment Exposure is Probably Decisive.
    Pignot G; Thiery-Vuillemin A; Walz J; Bigot P; Bensalah K; Gravis G; Barthélémy P
    Eur Urol; 2020 Aug; 78(2):e81-e82. PubMed ID: 32389444
    [No Abstract]   [Full Text] [Related]  

  • 10. Re: Bimal Bhindi, Jeffrey Graham, J. Connor Wells, et al. Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.04.038: Cytoreductive Nephrectomy: To Whom and When?
    Mollica V; Rizzo A; Massari F
    Eur Urol Oncol; 2020 Aug; 3(4):559-560. PubMed ID: 32553708
    [No Abstract]   [Full Text] [Related]  

  • 11. Surgical Safety of Deferred Cytoreductive Nephrectomy Following Pretreatment with Immune Checkpoint Inhibitor-based Dual Combination Therapy.
    Graafland NM; Szabados B; Tanabalan C; Kuusk T; Mumtaz F; Barod R; Nicol D; Boleti E; Powles T; Haanen JB; Bex A
    Eur Urol Oncol; 2022 Jun; 5(3):373-374. PubMed ID: 34933813
    [No Abstract]   [Full Text] [Related]  

  • 12. Re: Bimal Bhindi, E. Jason Abel, Laurence Albiges, et al. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma. Eur Urol 2019;75:111-28: Cytoreductive Nephrectomy in the Targeted Therapy Era: This is Not the End.
    Massari F; Di Nunno V; Santoni M; Gatto L; Mollica V; Porta C
    Eur Urol Oncol; 2019 Sep; 2(5):603-604. PubMed ID: 31411982
    [No Abstract]   [Full Text] [Related]  

  • 13. Reply to Xiaoshuai Gao, Guo Chen, and Xin Wei's Letter to the Editor re: Keiichiro Mori, Mohammad Abufaraj, Hadi Mostafaei, et al. The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis. Eur Urol 2021;79:783-92.
    Mori K; Schmidinger M; Egawa S; Gust KM; Shariat SF
    Eur Urol; 2021 Dec; 80(6):e145-e146. PubMed ID: 34579998
    [No Abstract]   [Full Text] [Related]  

  • 14. A Swinging Pendulum: Bringing Back Cytoreductive Nephrectomy in the Era of Immune Checkpoint Inhibition.
    Pallauf M; Ged Y; Singla N
    Eur Urol Oncol; 2022 Oct; 5(5):585-586. PubMed ID: 35965196
    [No Abstract]   [Full Text] [Related]  

  • 15. Re: Upfront Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors or Targeted Therapy: An Observational Study from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Liu J; Moon D; Lawrentschuk N
    Eur Urol; 2023 Aug; 84(2):244-245. PubMed ID: 37088596
    [No Abstract]   [Full Text] [Related]  

  • 16. Re: E. Jason Abel, Viraj A. Master, Philippe E. Spiess, et al. The Selection for Cytoreductive Nephrectomy (SCREEN) Score: Improving Surgical Risk Stratification by Integrating Common Radiographic Features. Eur Urol Oncol. 2023;6:266-274.
    Roussel E; Bertolo R; Ciccarese C; Marandino L; Marchioni M; Campi R; Albersen M;
    Eur Urol Oncol; 2024 Apr; 7(2):304-305. PubMed ID: 37981494
    [No Abstract]   [Full Text] [Related]  

  • 17. Re: Geraldine Pignot, Antoine Thiery-Vuillemin, Jochen Walz, et al. Nephrectomy After Complete Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma: A New Surgical Challenge? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.12.018: The Next Surgical Frontier in Kidney Cancer: Nephrectomy After Immune Checkpoint Inhibition.
    Singla N; Margulis V
    Eur Urol; 2020 Aug; 78(2):e79-e80. PubMed ID: 32362497
    [No Abstract]   [Full Text] [Related]  

  • 18. Radical Nephrectomy After Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma.
    Yanagisawa T; Schmidinger M; Kawada T; Bekku K; Kimura T; Shariat SF
    Eur Urol Focus; 2023 Mar; 9(2):275-277. PubMed ID: 36775716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Upfront Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors or Targeted Therapy: An Observational Study from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Bakouny Z; El Zarif T; Dudani S; Connor Wells J; Gan CL; Donskov F; Shapiro J; Davis ID; Parnis F; Ravi P; Steinharter JA; Agarwal N; Alva A; Wood L; Kapoor A; Ruiz Morales JM; Kollmannsberger C; Beuselinck B; Xie W; Heng DYC; Choueiri TK
    Eur Urol; 2023 Feb; 83(2):145-151. PubMed ID: 36272943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reply to Michael Staehler, Dena Battle, Axel Bex, Hans Hammers, and Daniel George's Letter to the Editor re: Arnaud Méjean, Alain Ravaud, Simon Thezenas, et al. Sunitinib Alone or After Nephrectomy in Metastatic Renal-cell Carcinoma. Eur Urol 2018;74:842-3: Lymphocyte Phenotype and Timing of Radical Nephrectomy in Patients Treated with Immunocheckpoint Inhibitors for Renal Cell Carcinoma.
    Santoni M; Montironi R; Battelli N; Massari F
    Eur Urol; 2019 Mar; 75(3):e64-e66. PubMed ID: 30391082
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.